Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: 9 - The Real Truth

Indonesia to produce Merck's HPV vaccines to combat cervical cancer

Indonesia will produce drugmaker Merck Co's vaccines for human papillomavirus (HPV), the chief of its state-owned pharmaceutical company Bio Farma said on Tuesday, in a bid to combat HPV-linked cervical cancer in the country.

Reuters

3 Stocks Insiders Can’t Stop Buying This Month

After signs of cooling inflation, investors are hopeful that the Fed will slow its rate hikes over the coming months. With surging optimism, fundamentally strong stocks Merck (MRK), Coca-Cola (KO), and Verizon (VZ), which have seen increased insider buying, might be ideal investments now. Continue reading.

StockNews.com

Uganda ends school year early as it tries to contain growing Ebola outbreak

Since the outbreak began in September, eight children have died — and there is no approved vaccine. But doctors are hopeful that public health measures may be enough to stop the spread.

WEKU

From analysis to the latest developments in health,
read the most diverse news in one place.

The COVID drug under a cloud that made billions

'It's a big deal because the Australian government purchased a huge amount of that drug.'

Newcastle Herald

This Health Care Stock Is a No-Brainer Buy for Fall

Merck & Co.’s (MRK) third-quarter financials surpassed Wall Street’s expectations. The stock is trading near its 52-week high of $101.50, and its momentum is expected to continue, considering its strong fundamentals. Given the company’s solid growth, reliable dividend payments, and the resilience of its sector against the expected economic slowdown,…

StockNews.com

Merck charged in France over failure to inform on changes to thyroid drug

The French unit of German pharmaceuticals firm Merck has been charged with willful commercial deception for failing to inform patients of changes to a thyroid treatment that could result in serious side-effects.

Radio France Internationale

Breakthrough cancer vaccine could be ready in months, say scientists

Manufacturers Moderna and Merck are testing a breakthrough cancer vaccine for patients suffering from melanoma which kills thousands of people each year in the UK

Daily Mirror

Read news from The Economist, FT, and more,
with one subscription

Amazon Halts Delivery Bots; Merck's Covid-19 Pill Didn't Reduce Risk; Samsung Profits Slip; Adidas Reviews Relationship With Kanye: Top Stories Friday, Oct. 7

Benzinga

3 Healthcare Stocks Under $100 to Buy Right Now

The rising prevalence of chronic diseases and the aging population are major growth drivers for the healthcare industry. In addition, increased investments in technological advancements should further bolster the industry’s growth. Thus, we think it may be prudent to buy quality healthcare stocks Pfizer Inc. (PFE), Merck & Co. (MRK),…

StockNews.com

2 Reliable Drug Stocks to Buy and Hold for Big-Time Gains

Persistent rate hikes by the Fed and rising odds of a recession have aggravated market turbulence and led investors to seek refuge in defensive sectors such as healthcare. Defensive stocks tend to perform well in declining markets due to the steady demand for their products. Hence, consistent dividend-yielding drug stocks…

StockNews.com

Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary

Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), the study met its primary endpoint for both the 50mg and 28mg EFX dose groups. Akero Therapeutics shares…

Benzinga

Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia. Spectrum Pharmaceuticals shares traded as high as 3.17 percent, in a range of $1.21 to $1.30 on day volume of 6.8 million…

Benzinga

5 Dividend Stocks to Buy and Hold Forever

Persistent economic turbulence and an uncertain outlook have led investors to prioritize steady income generation from their investments. Hence, fundamentally sound dividend yielders with a solid track record and potential for perpetual growth Merck (MRK), Abbott (ABT), Cigna (CI), Energy Transfer (ET), and Kronos (KRO) could be permanent additions to…

StockNews.com

Benzinga Before The Bell: Elon Musk's Demand For Broad Twitter Data Dismissed, Xiaomi Wants To Join EV Race, Bed Bath & Beyond Plans To Share Turnaround Strategy Next Week And Other Top Financial Stories Friday, August 26

CNBC The Aviation Sector Is Slammed By Sky-High Rents

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

Pfizer (NYSE:PFE) announced positive top-line data from the Phase 3 clinical trial RENOIR investigating its bivalent RSV prefusion F vaccine candidate, RSVpreF, when administered to adults 60 years of age or older. Pfizer, Inc. shares traded in a range of $47.27 to $47.95 on day volume of 14.45 million shares, closed…

Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck's (NYSE:MRK) lead asset MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease (ESRD). Merck shares traded in a range of $89.72 to $90.97 on day volume of 5.2…

Financial Times

How science is getting closer to a world without animal testing

New technology involving miniature human organs built in a lab is a step towards better treatments and ending a contentious practice

Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug Application (NDA) for elacestrant for patients with ER+/HER2- advanced or metastatic breast cancer. The agency has granted Priority Review designation and assigned a target action date of February 17, 2023. Radius Health…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Tribune News Service

Merck & Co.’s Januvia, a popular diabetes drug, was found to be contaminated with a potential carcinogen.

Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline B

Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ:MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. MediWound shares traded in a range of $1.6 to $1.76 on a day…

Benzinga

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.